A study reveals AI's role in identifying antimicrobial compounds for tuberculosis, enhancing drug development through ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues ...

His research explores the rise of generative AI and accelerated use of AI more broadly to advance drug and scientific discovery. Reuben leads Gartner's coverage of genomics, multiomics, cell and gene ...

Set to enter hospice care, a patient with idiopathic multicentric Castleman's disease is now in remission after treatment with a medication identified by an AI-guided analysis.

is a drug discovery company that utilizes generative AI, reverse immunology, and proprietary synthetic biology tech in its drug-creation platform to rapidly identify antibodies produced by super ...

With the advent of artificial intelligence (AI), the industry witnessed a rapid transformation in early disease detection, genomic research, drug discovery, clinical processes, and treatment efficacy ...

we adopt a naming convention of “PDBID” + “antibody fragment” (e.g., 4WEB Fab). The biological and physicochemical properties play a crucial role in the new drug discovery pipelines for therapeutic ...

*Corresponding Author: Leif W. Ellisen, MGH Cancer Center, CPZN-4204, 185 Cambridge Street, Boston, MA 02114. E-mail: [email protected] Clin Cancer Res 2025;XX:XX–XX R.O. Abelman, B. Wu, and H. Barnes ...

Additionally, in February 2023, Keymed and Lepu Biopharma’s joint venture KYM received $63m from AstraZeneca for early-phase antibody-drug conjugate (ADC) CMG901, highlighting the company’s growing ...

Former President Donald Trump will head back to the White House Monday, and while his final policy choices remain to be seen, he could push plans from a years-old platform that includes stricter ...

Currently, chemotherapy, targeted therapy, immunotherapy or combination therapy is the main treatment for NSCLC, but it is still inevitably faced with the challenges of acquired drug resistance and ...